# An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis

> **NCT02641730** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 159 (actual)

## Conditions studied

- Palmoplantar Pustulosis

## Interventions

- **DRUG:** Guselkumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02641730
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-15
- **Primary completion:** 2017-03-28
- **Final completion:** 2018-07-17
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02641730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02641730, "An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02641730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*